Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 14Endocrine 6Sarcoma 5Head & Neck 4Gastrointestinal 4Thoracic 3NET 3Tumor-Agnostic 2Gynecologic 2Dermatologic 2CNS 2Breast 1

Conditions

Neuroendocrine Tumors 2Non functioning pancreatic endocrine tumor 1Metastatic Digestive System Neuroendocrine Tumor G1 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Renal Cell 1Carcinoid Tumor 1Adenoma, Islet Cell 1

Interventions

lutetium Lu 177 dotatate 6Specimen Handling 4Magnetic Resonance Spectroscopy 4cabozantinib 3pembrolizumab 2olaparib 2fludarabine 2X-Rays 2Phantoms, Imaging 2Cyclophosphamide 2tivozanib 1repotrectinib 1pazopanib 1fludarabine phosphate 1entrectinib 1belinostat 1atezolizumab 1aldesleukin 1Yttrium-90 1Watchful Waiting 1Tomography, X-Ray Computed 1Tomography, Emission-Computed, Single-Photon 1Temozolomide 1Sunitinib 1Single Photon Emission Computed Tomography Computed Tomography 1Salts 1Positron Emission Tomography Computed Tomography 1PT-100 dipeptide 1Octreotide 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
cabozantinib × NET × 30 days × Clear all
NCT03375320 2026-06-03

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

National Cancer Institute (NCI)

Phase 3 Active not recruiting
298 enrolled 14 charts 1 FDA
EndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT05773274 2026-06-03

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
100 enrolled
EndocrineNET

Metastatic Digestive System Neuroendocrine Tumor G1

NCT05263050 2026-05-22

Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

Fox Chase Cancer Center

Phase 2 Recruiting
111 enrolled
EndocrineGenitourinaryNET

Clear-cell metastatic renal cell carcinoma, Carcinoid Tumor, Carcinoma, Renal Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡